GlobeNewswire Inc | Nov 4, 2020 08:00AM EST

November 04, 2020

AUSTIN, Texas, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aspira Womens Health, Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, today announced it will report financial results for the third quarter ended September 30, 2020 on Thursday, November 12, 2020 after the market close, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.

Thursday, November 12^th @ 4:30pm ETDomestic: 877-407-4018International: 201-689-8471Conference ID: 13712253Webcast: http://public.viavid.com/index.php?id=142095

About Aspira Womens Health Inc.Aspira Womens Health, Inc. (formerly known as, Vermillion inc.,Nasdaq:VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. ASPIRA is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis.OVA1plus includes our FDA-cleared products, OVA1and OVERAto detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXtesting offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, ASPIRA is delivering a portfolio of pelvic mass products over a patients lifetime with our cutting-edge research. The next generation of products in development are OVANEXand EndoCheck.Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:

Ashley R. Robinson LifeSci Advisors, LLC Tel 617-430-7577Arr@lifesciadvisors.com